On March 10, 2022, Sinopharm announced that its subsidiary Tianfang Co.
, Ltd.
Risedronate Sodium Tablets recently received the "Approval Notice for Supplementary Drug Application" approved and issued by the NMPA
.
Risedronate sodium tablet is a bisphosphonate drug, risedronate sodium has an affinity for hydroxyapatite crystals in bone, is a bone resorption inhibitor, suitable for the treatment and prevention of postmenopausal women.
Osteoporosis
.